Belanoff Joseph K's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Mar 27, 2026
- Accession no.
- 0001193125-26-129143
- Filed
- Mar 27, 2026
- Trade date
- Mar 25, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.31M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Belanoff Joseph KCIK 0001286199 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Common Stock | SSaleDisposed | −26,198 | $50.07F2 | −$1,311,733.86 | 2,918,326 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.